Mechanism of recovery from Hfq-induced growth inhibition by ansamycin family antibiotics
Project/Area Number |
15K14690
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Applied microbiology
|
Research Institution | Tokyo Institute of Technology |
Principal Investigator |
TAKADA AYAKO 東京工業大学, 技術部, 技術職員 (20401565)
|
Co-Investigator(Renkei-kenkyūsha) |
WACHI Masaaki 東京工業大学, 生命理工学院, 教授 (90192822)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | 抗生物質 / RNA代謝 / Hfq |
Outline of Final Research Achievements |
The aim of this study is to develop new antibiotics targeting RNA metabolism. We previously reported that overproduction of Hfq, an RNA chaperone, inhibits cell division by suppressing expression of the cell division protein FtsZ. It was found that rifampicin, an ansamaycin family antibiotic, recovered growth inhibition caused by Hfq-overproduction. Other ansamycin family antibiotics also recovered growth inhibition. Western blotting analysis showed that expression levels of Hfq were lowered upon rifampicin treatment. In rifampicin-resistant rpoB mutants, ansamycin family antibiotics did not recover growth inhibition. These results suggest that ansamycin family antibiotics recover growth inhibition by decreasing expression levels of Hfq via RNA polymerase.
|
Report
(4 results)
Research Products
(16 results)